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ACTH Receptor (MC2R) Specificity: 
what Do we Know About Underlying 
Molecular Mechanisms?
Davids Fridmanis*, Ance Roga and Janis Klovins
Latvian Biomedical Research and Study Centre, Riga, Latvia
Coincidentally, the release of this Research Topic in Frontiers in Endocrinology takes 
place 25 years after the discovery of the adrenocorticotropic hormone receptor (ACTHR) 
by Mountjoy and colleagues. In subsequent years, following the discovery of other types 
of mammalian melanocortin receptors (MCRs), ACTHR also became known as melano-
cortin type 2 receptor (MC2R). At present, five types of MCRs have been reported, all 
of which share significant sequence similarity at the amino acid level, and all of which 
specifically bind melanocortins (MCs)—a group of biologically active peptides gener-
ated by proteolysis of the proopiomelanocortin precursor. All MCs share an identical 
–H–F–R–W– pharmacophore sequence. α-Melanocyte-stimulating hormone (α-MSH) 
and adrenocorticotropic hormone (ACTH) are the most extensively studied MCs and 
are derived from the same region. Essentially, α-MSH is formed from the first 13 amino 
acid residues of ACTH. ACTHR is unique among MCRs because it binds one sole 
ligand—ACTH, which makes it a very attractive research object for molecular pharma-
cologists. However, much research has failed, and functional studies of this receptor are 
lagging behind other MCRs. The reason for these difficulties has already been outlined 
by Mountjoy and colleagues in their publication on ACTHR coding sequence discovery 
where the Cloudman S91 melanoma cell line was used for receptor expression because 
it was a “more sensitive assay system.” Subsequent work showed that ACTHR could 
be successfully expressed only in endogenous MCR-expressing cell lines, since in other 
cell lines it is retained within the endoplasmic reticulum. The resolution of this method-
ological problem came in 2005 with the discovery of melanocortin receptor accessory 
protein, which is required for the formation of functionally active ACTHR. The decade 
that followed this discovery was filled with exciting research that provided insight into the 
molecular mechanisms underlying the action of ACTHR. The purpose of this review is to 
summarize the advances in this fascinating research field.
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iNTRODUCTiON
Adrenocorticotropic hormone (ACTH), discovered in 1933 (1), is the primary regulator of aldos-
terone and corticosterone/cortisol production in mammalian adrenal glands (2–5). It is secreted 
into the circulating blood stream by corticotropic cells in the anterior pituitary (6) in response to 
short- and/or long-term stress (7). Due to its chemical structure, biological activity, and origin, 
FigURe 2 | Sequence alignment of melanocortin (MC) peptides. All MCs share the conserved –M–X–H–F–R–W– motif, which serves as the pharmacophore 
for receptor binding (8, 10). The –K–K–R–R–P– motif within adrenocorticotropic hormone (ACTH) is considered the second pharmacophore and is required for 
successful activation of adrenocorticotropic hormone receptor (26).
FigURe 1 | Schematic representation of the proopiomelanocortin precursor, the products of its proteolysis, and known posttranslational 
modifications. Melanocortins are colored green, signal peptide is colored red, and other peptides are colored blue. Posttranslational modification sites are marked 
with vertical black lines.
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ACTH is classified as a member of the peptide hormone group 
named melanocortins (MCs), which in addition to ACTH also 
comprises α-, β-, γ- and δ-melanocyte-stimulating hormones 
(MSHs), of which the latter is only found within cartilaginous 
fish (8). All MCs are formed through tissue- and site-specific 
proteolysis of the propeptide proopiomelanocortin (POMC; 
Figure 1) (7, 9), and all share the –M–X–H–F–R–W– consensus 
sequence (Figure  2), which is the main determinant of their 
biological activity (8, 10). Experimental data suggest that this 
core sequence adopts a β-turn secondary structure in most MCs 
that is generally essential for ligand binding (11). The exception 
to this rule is γ-MSH, but since it is not directly relevant to the 
main subject of this article, the reasons underlying this differ-
ence are not discussed [for details on molecular mechanisms 
underlying the action of this peptide see Ref. (12)]. α-MSH and 
ACTH are overlapping peptides since the aa sequence of the 
former is identical to the first 13 aa of the latter, because the 
former is the result of proteolytic cleavage of the latter (Figure 1). 
Following their discovery and aa sequence determination (1, 
13–19), there was an ongoing discussion about the melano-
tropic activity of ACTH and the possible adrenocorticotropic 
activity of α-MSH (13, 20). However, the latter of these was 
soon dismissed following overwhelming evidence from ex vivo 
assays that suggested ACTH-derived peptides, which lack the 
basic –K–K–R–R– motif (Figure  2), have minimal effect on 
steroid production [(21, 22); reviewed in Ref. (23–25)]. Detailed 
mutational research performed a few decades later extended this 
motif by including a C-terminal proline, since the replacement 
of this residue with alanine or tryptophan significantly decreased 
the potency of the peptide (26). A similar alanine scanning 
mutagenesis experimental approach was also used to investigate 
the properties of the ACTH region, which is located between the 
–M–X–H–F–R–W– and –K–K–R–R–P– motifs (Figure 2). The 
results demonstrated that although replacement of one or two 
residues had no effect on receptor activation, substitution of all 
five residues (–G–K–P–V–G–) resulted in dramatic decrease in 
response sensitivity. Thus, it was concluded that the secondary 
structure of this motif is of paramount importance because it 
properly orients the other two motifs in relation to each other 
so that they can properly fit into the receptor-binding pocket(s) 
(27). This highly condensed introduction to ACTH, the ligand 
of ACTHR that is the main subject of this review, barely skims 
the enormous amount of knowledge acquired for mammalian 
and other lineages (6, 8, 10, 28–37). However, although having 
a detailed understanding of the functional properties of the 
ligand is very import because the interaction of both elements 
results in the physiological effect, reviewing the ligand in detail 
is beyond the scope of this article. We believe the core informa-
tion provided here will be sufficient for interpretation of the 
research on the molecular mechanisms underlying the action of 
the adrenocorticotropic hormone receptor (ACTHR).
Although the main subunit of the receptor was discovered 
in 1992 (38) and the functional receptor was obtained in 2005 
(39), research on the structure and function of the mammalian 
ACTHR dates back as far as 1954, when the aa sequence of 
ACTH was determined (14–18), or perhaps even to 1933, when 
TAble 1 | ligand selectivity and expression profiles of melanocortin 
receptors.
Receptor Potency of ligands Site of expression
MC1R α-MSH = ACTH > β-MSH > γ-MSH Melanocytes
ACTHR ACTH Adrenal cortex, adipocytes
MC3R α-MSH = β-MSH = γ-MSH = ACTH Hypothalamus, limbic 
system, placenta, 
digestive tract
MC4R α-MSH = ACTH > β-MSH > γ-MSH Hypothalamus, limbic 
system, cerebrum, brain 
stem
MC5R α-MSH > ACTH > β-MSH > γ-MSH Muscles, liver, spleen, 
lungs, brain, adipocytes
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the hormone itself was discovered (1). Although to some readers 
this statement might seem exaggerated, ex vivo research on the 
physiological effects of ACTH was performed on tissue samples 
containing endogenously expressed ACTHR from these dates. 
Thus, a large amount of knowledge was accumulated well before 
the discovery of the receptor itself, and some of these early 
studies revealed that the receptor was also present in murine 
fat cells (40–42) and in addition to increasing corticosteroid 
production (1, 43), activation of the ACTHR is accompanied by 
the activation of phosphorylases (44, 45), an increase in cyclic 
adenosine 3′,5′-monophosphate (cAMP) concentration (46–50), 
and subsequently desensitization (51). Research performed in the 
1980s also revealed that stimulation with ACTH increases the 
number of ACTH-binding sites at adrenal cell membranes (52) 
and promotes calcium influx (53–56). The information gained 
during these studies was extensive, and it provided researchers 
with clues on the nature of the ACTHR and accelerated research 
in related areas.
At the beginning of the 1990s, a significant number of 
G-protein coupled receptors (GPCRs) were already identified, all 
of which share the typical seven transmembrane (TM) domain 
core structure with the N-terminus located on the exterior of the 
cell. These receptors were shown to activate intracellular signaling 
pathways through coupling to the α-subunit of heterotrimeric 
G-proteins (Gα) that comprise also β and γ subunits. At the time, 
it was already known that there are several types of G-proteins 
that induce distinct intracellular responses (57). The most notable 
of these from the perspective of melanocortin receptors (MCRs) 
and the ACTHR were those coupling to the Gαs subunit that 
activates adenylyl cyclase, which in turn increases the intracel-
lular concentration of cAMP. This knowledge was consistent 
with the observed ACTH-induced intracellular responses, which 
indicated that MCRs are members of this structurally conserved 
GPCR family.
The coding sequences of receptors that specifically bind 
ACTH were first reported in 1992 by two research groups, one 
led by Cone, and the other led by Wikberg (38, 58). Although 
both groups employed similar methodology (degenerate primer 
PCR followed by northern blot screening of melanoma cDNA 
libraries), the first group identified two receptor-encoding genes, 
and the second group identified one such gene. This discrepancy 
could partially be explained by the source of the PCR template, 
since Cone’s group used cDNAs from melanoma cells, while 
Wikberg’s group used genomic DNA. Subsequent pharmacologi-
cal characterization of receptors and post-publication sequence 
comparison revealed that both groups discovered the same MCR, 
which is highly expressed within melanocytes and specifically 
binds all MCs (ACTH, α-, β- and γ-MSH), and was thus desig-
nated the MSH receptor (MSHR) (38, 58). In addition to MC1R, 
Cone’s group also discovered a receptor sharing significant aa 
sequence identity with MSHR (~39%), yet it proved to be difficult 
to characterize in vitro. Functional expression of this protein was 
achieved only in an endogenous MCR-expressing Cloudman S91 
melanoma cell line, and unlike MSHR, this receptor was found 
to be expressed in adrenal tissue and activated only by ACTH 
and was hence named the ACTHR (38). In the following 2 years, 
three additional MC-binding receptors were uncovered—two 
by Yamada’s group (59, 60) and one by both the Wikberg’s and 
Yamada’s groups (61, 62). Due to this simultaneous discovery, 
there was some ambiguity in the nomenclature of these novel 
MCRs, but the scientific community soon came to agreement 
and named them using Yamada’s nomenclature as the MC type 
3 receptor (MC3R), MC4R, and MC5R. Evaluation of the phar-
macological properties of these novel receptors revealed that, like 
previously characterized homologs, they all coupled with Gαs [it 
was later discovered that the exception to this rule is MC3R, which 
is also able to interact with the Gαq/11 subunit (63)]. However, 
from a ligand selectivity and in  vitro expression perspective, 
they are more akin to MSHR since they are activated by all four 
MCs and successfully expressed in non-melanoma cells. Since 
these new receptors also shared significant aa sequence identity 
with previously discovered homologs (all MCRs share 39–61% 
sequence identity), their nomenclature was reviewed and, as a 
result, MSHR became synonymous with MC1R, and ACTHR 
with MC2R. To avoid any further confusion, in this article, we use 
ACTHR throughout, since this name better describes the unique 
functional properties, while the HGNC approved name of MC2R 
is a better descriptor of its evolutionary origin.
Considered together, the results on MCR expression and 
ligand selectivity highlighted the unique nature of each recep-
tor because all displayed distinct pharmacological and tissue 
distribution profiles (Table 1). From this perspective, MC3R and 
ACTHR are the most specialized MCRs, because MC3R is the 
only receptor in this family that effectively binds γ-MSH and, as 
mentioned above, ACTHR specifically binds only ACTH (64). 
The molecular mechanisms underlying the ability of MC3R to 
effectively bind γ-MSH were soon uncovered (12, 65) following 
the expression of this receptor in a variety of mammalian cell 
lines. However, the mechanisms underlying the ACTHR ligand 
selectivity remained concealed for more than a decade due to the 
unusual expression selectivity of this receptor.
Although the period following the determination of the DNA 
sequence encoding the ACTHR was marked by very few molecu-
lar studies, this knowledge did facilitate functional and genetic 
research, which confirmed expression in the zona reticularis 
and zona fasciculata of the adrenal cortex, where its activation 
upregulates its own mRNA production (66). ACTHR mRNA was 
also found to be present in murine adipocytes (67–69) [where 
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it affects lipolysis (67, 70) as well as leptin (71) and interleukin 
6 production (69)], skin (72–74), pituitary (75), rat sympathetic 
ganglia (76), fetal and neonatal mouse testis (77, 78), human 
endometrium (79), human erythroblasts (80), and human 
osteoblasts (81, 82). The concept of receptor desensitization was 
not forgotten and was investigated in detail, and findings were 
somewhat contentious, but all agreed that receptor phosphoryla-
tion by various kinases (GPCR kinase and protein kinases A and 
C) is essential for desensitization and subsequent internalization 
via clathrin-coated pits (83–87).
There are several disorders associated with aberrant ACTH 
action. Familial glucocorticoid deficiency (FDG), which is 
also known as familial glucocorticoid insufficiency, heredi-
tary adrenocortical unresponsiveness to ACTH, and familial 
Addison’s disease, is a rare, early onset, autosomal recessive 
disorder characterized by low or undetectable plasma cortisol 
levels, normal mineralocorticoid levels, excess plasma ACTH, 
and hypoplasia of adrenal cortex zona fasciculata and zona 
reticularis. Typical physical symptoms include frequent hypogly-
cemia and/or infective episodes accompanied by excessive skin 
pigmentation. This disease was described in detail for the first 
time by Shepard in 1959 (88), and other studies soon followed 
(89–96). All reports highlighted an unusual resistance to ACTH 
in patients and a positive response to glucocorticosteroid treat-
ment. Nevertheless, until 1993, when the first mutations within 
ACTHR coding sequence were discovered (97), the genetic cause 
of this disorder remained unknown. From this pivotal moment, 
the number of reports involving sequencing of ACTHR, which is 
located on the small arm of chromosome 18 (18p11.21-pter) (98), 
increased significantly (99–101) and facilitated accumulation of 
some structural information that is reviewed in a separate chap-
ter. However, although this information did provide some clear 
links between genetic cause and physiological effect, surprisingly, 
mutations within ACTHR were the cause of FGD in only 25% of 
cases, indicating additional ACTHR-related factors. In the after-
math of these initial genetic discoveries, the disorder caused by a 
faulty ACTHR gene was designated as FDG type I, while disorders 
of unknown cause were designated FDG type II (100, 102–104).
As the incoming information from genetic studies was in a 
good agreement with the difficulties in expressing ACTHR, 
interest remained intense and molecular research continued. 
The first breakthrough was achieved in 1995 when Schimmer 
and colleagues revealed that ACTH-resistant Y6 and OS3 cell 
lines derived a decade earlier from the Y1 adrenal cell line (105) 
completely failed to express ACTHR (106). This provided for the 
first time a platform for sensitive and unbiased ACTHR char-
acterization (107–109). An important study using one of these 
cell lines was performed by Noon and colleagues who expressed 
an ACTHR-green fluorescent protein (GFP) fusion protein and 
observed that the receptor is retained within the endoplasmic 
reticulum (ER) of CHO cells, but successfully reached the cell 
membrane in Y6 cells. Thus, they concluded that adrenal cells 
produce some kind of ACTHR accessory factor that overcomes 
receptor trafficking arrest (110).
The discovery of this accessory factor was reported in 2005 
by Metherell and colleagues (39) who performed SNP array 
genotyping on an FGD type 2 family to map the causal mutation 
to chromosome 21 locus 21q22.1, which spanned 30 known 
or predicted genes at the time. Subsequent in silico and mRNA 
expression analyses revealed that one of these genes, a predicted 
small single TM domain protein encoding a six exon gene 
named “chromosome 21 open reading frame 61 (C21orf61),” was 
expressed in adrenals and carried a mutation within the third 
intron donor splice site. In vitro co-expression of this protein 
with ACTHR-GFP in CHO and SK-N-SH cells confirmed that 
the receptor successfully reached the cell membrane and was 
functionally active. Based on these results, the newly identi-
fied protein was renamed the melanocortin receptor accessory 
protein (MRAP). Following the confirmation of its functional 
purpose, Matherell and colleagues performed an in-depth analy-
sis of the gene and its expression profile. They discovered two 
isoforms of MRAP resulting from alternative splicing: MRAP-α 
and MRAP-β. The 172 aa MRAP-α is the product of the first five 
exons, while the 102 aa MRAP-β is formed from the third, fourth, 
and sixth exons. Since the “Start” codon is located within the third 
exon, both isoforms have identical N-termini and TM domains, 
but distinct C-termini. Analysis of protein expression patterns 
revealed that both proteins are differentially expressed in various 
tissues. Simultaneous expression was observed in the adrenals, 
testis, breast, ovary, adipocytes, skin, and jejunum. MRAP-α is 
also expressed in the thyroid, lymph nodes, ileum, liver, stom-
ach, and pituitary, while MRAP-β is only expressed in the brain 
(39). It was later revealed that mutations in MRAP account for 
another 20–25% of FGD cases, thus it was established that there 
are additional causal factors for this disease that distinguish FGD 
type 2 and FGD type 3, the later referring to cases of unknown 
genetic cause (111).
As would be expected, the discovery of MRAP stimulated 
research aimed at uncovering the molecular mechanisms of 
ACTHR action. However, it also initiated an additional line 
of research aimed at investigating MRAP itself. These studies 
demonstrated that ACTHR is differentially affected by MRAP 
isoforms, with MRAP-α providing higher sensitivity to ACTH, 
whereas higher cAMP response and membrane trafficking occur 
during co-expression with MRAP-β (112). Detailed investiga-
tions on the actions of the accessory proteins revealed a unique 
feature; in the cell, MRAP is present as a highly stable, SDS-
resistant, antiparallel homodimer in which the C-terminus of 
one monomer is on the cytoplasmic side of the cell membrane, 
while the C-terminus of the other is on the extracellular side 
of the cell membrane (113, 114). A few years later, the same 
dimer topology was also observed in another membrane protein 
sharing 39% aa sequence identity with MRAP that was also able 
to facilitate ACTHR trafficking to the cell membrane, and this 
evolutionary related protein was therefore named MRAP2 (115). 
There was, however, one major difference between MRAP1 (the 
name was accordingly updated) and MRAP2; when co-expressed 
with MRAP2, ACTHR was located on the surface of the cell, but 
stimulation with ACTH induced the cAMP response with 1000-
fold lower potency than when co-expressed with MRAP1 (116). 
This observation indicated that MRAP1 is more than a mere 
“deliverer” and is instead an essential functional component of 
ACTHR (115). Indeed, it was soon discovered that the N-terminal 
region comprising residues 18–21 (–L–D–Y–L–) is essential for 
FigURe 3 | Formation of functionally active adrenocorticotropic hormone receptor (ACTHR). The functional form of ACTHR is a hetero-hexameric structure 
formed from two molecules of ACTHR and four molecules of MRAP1. The antiparallel dimer of MRAP1 is formed within the endoplasmic reticulum, where it couples 
to one molecule of ACTHR. Afterward, this complex is transported to the Golgi where it “dimerizes,” thus forming the hetero-hexameric functional ACTHR (128). 
Symbols representing ACTHR and MRAP1 were selected to highlight the protein secondary structure. The depicted intermolecular interactions are therefore general 
and do not reflect the actual situation in detail.
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ACTHR ligand recognition (117). Its substitution with alanine 
residues resulted in an MRAP2-like protein that promoted only 
the trafficking of receptors to the plasma membrane. Alignment 
of both MRAPs revealed that this is the exact region missing 
from the MRAP2 sequence, and its insertion using site-directed 
mutagenesis allowed MRAP2 to form a functionally active 
ACTHR (117, 118). Further mutagenesis of various MRAP1 
regions also revealed that the N-terminal side of TM region, 
formed from residues 31–37 (–L–K–A–N–K–H–S–), is required 
for MRAP1 to form an antiparallel dimer, since its removal 
resulted in the formation of a protein with the N-terminus 
always oriented on the extracellular side of the cell membrane 
(117). Additional aa replacement experiments showed that the 
TM domain of MRAP1 provides specific coupling to ACTHR, 
although the nature of this interaction remains unclear (117, 
118). It should be noted that this review only considers MRAP1 
in relation to ACTHR, but the functions of this protein extend 
beyond formation of functionally active ACTHR (115, 119–123).
The latest development in the field of ACTHR research regards 
the dimerization of the receptor itself. It has been known for a 
long time that various GPCRs form homo- and heterodimers 
and that dimerization is essential for the formation of function-
ally active receptors and implementation of their physiological 
effects (124–126). Therefore, the discovery of MCR homo- and 
heterodimerization was not surprising (127). However, initial dif-
ficulties with expression prevented such experiments on ACTHR, 
but this changed in 2011 when Cooray and colleagues performed 
bioluminescence resonance energy transfer analysis on function-
ally active ACTHR (the ACTHR and MRAP1 complex) which 
revealed that, just like other GPCRs, ACTHR formed dimers. 
Furthermore, only when each ACTHR subunit was accompanied 
by an MRAP1 dimer was a functionally active ACTHR formed, 
hence the realization that a hetero-hexameric structure is required 
for full activity (Figure 3) (128).
Finally, we would like to highlight the important contribution 
made by ACTHR knock-out mice. Phenotypic data from these 
animals were in a very good agreement with observations by 
medical practitioners on the effects of ACTHR deficiencies in 
humans. ACTHR knock-out mice therefore provided an experi-
mental system for investigating the complexity of ACTHR action 
in mammals (129–134), but these studies are too voluminous and 
are beyond the immediate scope of this article.
MCs AND MCRs
More targeted research aimed at understanding the molecular 
mechanisms that underlie the action of MCRs was undertaken 
soon after their discovery. The majority of these studies focused 
on MC1R or MC4R, as they were either considered the best 
representatives, or the pharmacologically most relevant MCRs. 
Some research was also carried out on MC3R and MC5R, but 
due to expression difficulties, targeted studies on ACTHR were 
not performed until after 2000. Nevertheless, despite being 
highly specific, ACTHR is a member of the MCRs family and 
thus general MCR ligand-binding mechanisms are relevant and 
likely to apply.
Among the first to explore these mechanisms through active 
intervention were Frandberg and colleagues who performed 
PCR-based site-directed mutagenesis, a novel method at that 
time, to substitute selected aa residues with alanine to evaluate 
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the role of four human MC1R aa residues (D117, H260, F179, and 
H209) in ligand recognition and receptor activation. The selec-
tion criteria for these residues were the location within the 
TM domains, the presence of reactive groups, and sequence 
conservation between known MCRs. The employment of the 
last two criteria was somewhat traditional, since reactive groups 
are necessary for molecular interactions, whereas the degree of 
conservation indicates structural and/or functional importance 
of residue. However, the first criterion was unusual because 
known binding pockets for the majority of receptors were on 
their surface. MCRs were the smallest known GPCRs, and they 
bind relatively large peptide ligands, thus it was predicted that 
their binding pocket would be located between the helices. The 
results of these experiments revealed that two residues of the four 
(D117 and H260) were essential for binding of α-, β- and γ-MSH 
peptides, while their substitution had no effect on coupling 
with artificial ligand NDP-MSH ([Nle4,d-Phe7]-α-MSH). This 
demonstrated not only the importance of these residues but also 
the principle that different ligands may interact with different 
regions of the binding pocket (135).
Researchers employed a more sophisticated approach in one 
subsequent study; instead of creating a large number of recep-
tors by mutating conserved residues, they generated a three-
dimensional molecular model of human MC1R based on the 
cryo-electron microscopy structure of bacteriorhodopsin and the 
electron density footprint of bovine rhodopsin and docked sev-
eral natural and synthetic ligands. The results suggested the cavity 
of MC1R consists of two distinct acidic- and aromatic-binding 
pockets. According to this model, the acidic pocket is formed 
from E94 (TM2), D117 (TM3), and D121 (TM3), while the aromatic 
pocket is formed from F175 (TM4), F179 (TM4), F195 (TM5), F196 
(TM5), F257 (TM6), Y182 (TM4), and/or Y183 (TM4). Being acidic, 
the first pocket interacts with basic R residues and to some extent 
H residues in the MC consensus motif –M–X–H–F–R–W–, while 
the second pocket interacts with aromatic F and W residues of 
the same motif (136). In the following years, this research group 
rigorously tested this model with various point mutations, dif-
ferent native and synthetic ligands, and even through conversion 
to MC4R. Their results confirmed that residues in the predicted 
acidic pocket were of paramount importance for ligand binding 
and do indeed interact predominantly with R residue from the 
–M–X–H–F–R–W– motif. Data on the aromatic-binding pocket 
were harder to interpret because considerable alterations in 
ligand binding were achieved only when multiple mutations were 
introduced at the same time, suggesting each individual residue 
plays a small part, and the loss of one may be compensated by the 
others. However, this conclusion was not supported by an acidic 
pocket eradication experiment in which all three pocket-forming 
residues were replaced with alanines. The resulting receptor was 
functionally inactive yet able to bind α-MSH with modest affin-
ity, indicating other potentially more important ligand-binding 
elements within the aromatic pocket. Thus, the repertoire of 
mutated aromatic residues was extended, and W254 (TM6), Phe257 
(TM6), and H260 (TM6) were recognized as crucial elements of 
this ligand-binding pocket (137–139). In the following years, this 
type of research was performed on all five MCRs, which high-
lighted the uniqueness of the individual receptor-binding pockets 
by identifying the aa residues responsible for differential ligand 
recognition. However, all studies agreed that the six previously 
mentioned aa residues (Figure  4) form the “backbone” of the 
MCR-binding pocket, while the residues surrounding these act 
as binding pocket “modifiers” [(65, 140–143); reviewed in Ref. 
(144–147)].
An interesting attempt to redesign the three-dimensional 
model of MC4R was undertaken by Pogozheva et al. (149) and 
Chai et  al. (150). Unlike previous groups, these researchers 
employed data from functional analysis of receptors with point 
mutations and also used the crystal structure of bovine rhodopsin 
which had been recently determined (150). In addition, to test the 
validity of their model, they also performed docking of various 
native and artificial ligands. According to their model, the binding 
pocket of MC4R is a large elongated cavity formed by L44, V46, F51, 
E100, I103, I104, D122, I125, D126, I129, C130, L133, F184, S188, S190, V193, C196, 
M200, W258, F261, H264, L265, Y268, M281, F284, L288, and M292. This cavity 
contains several acidic and multiple aromatic residues located in 
groups on opposing sides thus forming the predicted-binding 
pockets with “backbone” MC-binding residues (Figures  4 and 
5). Although hypothetical, this model clearly demonstrates that 
a significant amount of space is required to incorporate the rela-
tively large β-turn structure of MCs (148), and a similar situation 
would be expected with all MCRs (links to models are available 
at http://www.uniprot.org/uniprot/P32245).
In the following years, a number of groups generated 3D mod-
els of various MCRs, and each explored MCR-specific themes, 
whether mutation-induced structural changes or differences in 
ligand recognition. However, the majority of these models are 
unavailable for download, and we were therefore unable to assess 
their intramolecular and intermolecular interactions in detail. 
For this reason, we used the model generated by Pogozheva et al. 
(148) and Chai et al. (149) as a reference in our following analysis.
NATURAllY OCCURRiNg MUTATiONS
Historically, the first source that provided information on the 
molecular mechanisms underlining the action of ACTHR were 
genetic studies on FGD—a rare autosomal recessive disorder 
that, as mentioned in Section “Introduction,” can be caused by 
defects in the ACTHR gene. From a genetic standpoint, all these 
alterations can be subdivided in three groups: mutations within 
regulatory sequences, mutations that result in severely truncated 
proteins (frameshift mutations or mutations that introduce STOP 
codons), and mutations that alter a single aa residue. Since the 
first two groups, from perspective of this article, are uninforma-
tive, they are not reviewed in detail [for reports on this subject see 
Ref. (107, 151–160)]. However, the third group has provided the 
scientific community with some valuable knowledge.
The first report on a missense mutation within FGD patients 
was published by Clark and colleagues soon after the discovery 
of the ACTHR coding sequence (97). The mutation was located 
within the extracellular part of the TM2 domain and resulted 
in substitution of S74 with I (Figure 6). Subsequent functional 
characterization of the mutated receptor confirmed that its 
ability to induce cAMP (107, 161, 162), bind ACTH (107), and 
even reach the cellular surface (despite being able to couple to 
FigURe 4 | Amino acid sequence alignment of human melanocortin receptors (MCRs). +--+ and vertical dashes mark transmembrane domain boundaries, 
acquired from GPCRdb (http://gpcrdb.org/). *Indicates residues that form the “backbone” of the MCR-binding pocket. ^Indicates residues that are unique to 
adrenocorticotropic hormone receptor (ACTHR). Red boxes indicate amino acid residues that, according to the model created by Pogozheva et al. (148) and Chai 
et al. (149), form the ligand-binding cavity of MC4R.
FigURe 5 | Cartoon representation of the backbone of the MC4R model created by Pogozheva et al. (148) and Chai et al. (149). (A) View from the side 
and top on the surface of the ligand-binding cavity that contains several acidic (red) and multiple aromatic residues (blue) located in groups at opposite sides of the 
cavity and forming acidic- and aromatic-binding pockets, respectively. (b) Close-up view of the binding cavity without the surface layer.
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MRAP1) (156) was severely reduced in comparison to wild-type 
(WT) ACTHR. As expected, the discovery of this mutation was 
soon followed by others, and at present 35 different coding 
sequence alleles have been associated with adrenocortical dis-
orders (detailed information on these mutations is summarized 
in Table 2; Figure 6).
FigURe 6 | Snake-like plot of adrenocorticotropic hormone receptor (ACTHR). Forked structures represent glycosylation. –S–S– represents disulfide bonds. 
Circles with a red outline represent naturally occurring missense mutations (labels enclose information on the resulting residue replacement). Red labels indicate 
residues located on the extracellular part of the receptor. Green labels indicate residues located within the central part of transmembrane domains. Blue labels 
indicate residues located within the intracellular part of receptor. Dark green circles represent residues that form the backbone of the melanocortin receptor 
(MCR)-binding pocket. Orange circles represent residues equivalent to those forming the ligand-binding cavity of MC4R based on the model created by Pogozheva 
et al. (148) and Chai et al. (149). Light green circles represent residues that Yang et al. (146) identified as important for ligand recognition. Circles shaded in red, pink, 
and light purple represent residues equivalent to those that, according to the ADRB2 model (163), directly interact with Gα, are involved in Gα coupling-related 
intramolecular interactions, and that form the surface of the Gα-binding cavity, respectively. Circles shaded in black represent S/T residues that are crucial for 
ACTHR expression and functional regulation. Circles with angled cross-hatching represent residues that are unique to ACTHR (yet conserved in other MCRs).
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From a functional point of view, these mutations can be 
divided into three groups: (1) those located within the intracel-
lular part of the receptor (Table 2; blue labels in Figure 6) that 
are most likely to affect G-protein interactions; (2) those located 
on the extracellular part of the receptor (Table 2; red labels in 
Figure 6) that are most likely to affect receptor–ligand interac-
tions; (3) those located within the central regions of TM domains 
(Table 2; green labels in Figure 6) that are most likely to affect 
the overall conformation of the receptor. Despite the fact that this 
division is quite general, it is in good agreement with data from 
modeling of the MCR-binding pocket (148) and also the crystal 
structure of the β2 adrenergic receptor–Gs protein complex (163).
The majority of extracellular mutations altered either the 
previously mentioned “backbone” MC-binding residues (dark 
green in Figure 6), as is the case for D103 and D107, or residues that 
are adjacent to other MC ligand cavity-forming residues (orange 
in Figure 6). According to the model, MC4R-S259 (ACTHR-A233) 
and the conserved MC4R-P260 (ACTHR-P234) are located 
between aromatic-binding pocket-forming residues MC4R-W258 
(ACTHR-W232) and MC4R-F261 (ACTHR-F235) (Figures  4 
and 6). The presence of conserved P within the TM domain is 
rather unusual, since due to its chemical structure it is unable to 
participate in the formation of an α-helix, and when present it 
introduces a “kink”-like structure that is often employed for the 
proper positioning of surrounding reactive aa residues. Indeed, 
this appears to be exactly the case for MC4R-P260 (ACTHR-P234), 
and it is logical to presume that additional proline located adjacent 
to this conserved one, as is the case of ACTHR-A233 → P, would 
not only disrupt the binding pocket but also alter the overall 
conformation of the receptor to the extent that it is recognized as 
misfolded and retained within intracellular compartments and 
ultimately degraded.
According to both the model and other experimental data, 
there are two structure-stabilizing disulfide bonds within the 
extracellular region of MCRs (148, 183, 184). It is presumed that 
in the case of ACTHR these are formed between C245 and C251, 
and between C21 and C253 (Figure 6). Both the MC4R model and 
predictions using the NetTurnP 1.0 server (185) indicate that the 
bond between this first pair of residues “locks” the conserved 
–P–Q–N–P–Y– motif of extracellular loop (EL) 3 into a β-turn-
like structure, thus exposing its N and Y residues to the entrance 
of the binding pocket, and this also limits the physical distance 
TAble 2 | Amino acid residue replacements of naturally occurring ACTHR gene missense mutations and their effects on receptor function.
Mutation binding Cyclic adenosine  
3′,5′-monophosphate (cAMP)
basal cAMP activity Membrane 
trafficking
Reference
ECC21 → R ↓ ↔ (164, 165)
ECC21 → Y (166)
TMV45 → I ↔ ↔ (159)
ICV49 → M (153)
ICL55 → P ↓ (156)
TMS74 → I ↓ ↓ ↓ (97, 107, 108, 156–158, 161, 162)
ECD103 → N ↓ ↓ ↑ ↔ (107, 156, 167–170)
ECD107 → N ↓ ↓ ↔ (156, 159, 171–173)
TMG116 → V ↓ ↓ (156, 174)
TMS120 → R ↓ (151, 156)
ICA126 → S ↓ (160)
ICR128 → C ↓ ↓ ↔ (107, 156, 158)
ICY129 → C ↓ ↓ (156, 175)
ICI130 → N ↓ (156, 176)
ICR137 → W ↓ ↓ (108, 156)
ICH139 → Y ↓ (156, 176)
ICV142 → L ↓ (167–169)
ICR146 → H ↓ ↓ ↑ ↓ (107, 156–158, 166, 177)
TMT152 → K ↓ (156, 178)
TMT159 → K ↓ ↓ ↑ ↓ (107, 156, 179)
ECH170 → L ↓ ↔ (156)
ICL198 → P ↓ (156, 176)
TMG226 → R ↓ (156)
ECA233 → P ↓ ↓ (156, 168, 169)
ECS247 → G ↓ ↔ (164, 165)
ECC251 → F ↓ ↓ (156, 159, 171, 172)
ECY254 → C ↓ ↓ (108, 156, 180, 181)
ECS256 → F ↓ (156)
ICP273 → H ↓ ↓ (156, 162)
ICF278 → C ↔ ↔ ↑ ↔ (109, 175)
ICP281 → fs (173)
ICK289 → fs ↓ (182)
ICM290 → Stop ↓ (182)
ECC21 → R  
+  
ECS247 → G
↑ (164)
ICY129 → C  
+  
ICF278 → C
↓ ↓ (175)
EC, located within the extracellular part; IC, located within the intracellular part; TM, located within the central part of the TM domain; fs, frameshift; ↔, functional properties were 
unaffected; ↑, functional properties were improved; ↓, functional properties were hampered; empty field, no data available.
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between TM6 and TM7. Although data on the role of “locked” 
aa residues in MCR ligand recognition is ambiguous, the disrup-
tion of this disulfide bond (C251 → F) apparently prevents proper 
receptor folding and results in intracellular retention. From 
this perspective, it is hard to explain the negative effect of the 
S247 → G mutation, because according to model, the side chain of 
the residue homologous to ACTHR-S247 in MC4R is located on 
the exterior surface of the receptor and thus cannot be involved 
in ligand recognition. Perhaps the function of this β-turn-like 
structure is to serve as a physical barrier that restricts the move-
ment of the ligand while it occupies the cavity, or as a physical 
support that keeps the cavity entrance open. Thus, replacement 
of S274 with most other residues would not have any effect, but 
replacement with the highly flexible G allows it to adopt an alter-
native conformation that does not provide the necessary physi-
cal support. The disulfide bond between C21 and C253 connects 
TM1 and TM7 domains and locks the TM domain bundle in a 
“closed” conformation, which reduces flexibility and the number 
of available conformations. This effect appears to be crucial for 
formation of a functionally active receptor, as the disruption of 
this bond by C21 → R or C21 → Y mutations resulted in receptors 
incapable of binding ACTH. One possible explanation is prob-
ably connected to fact that the surface of the MCR ligand-binding 
cavity is predominantly formed from the TM domains. Another 
mutation that falls within the disulfide bond category is Y254 → C, 
since it introduces an additional C residue within the EL3 region 
that could interfere with the formation of one or other of the 
previously mentioned disulfide bonds. Therefore, unsurprisingly, 
the Y254 → C mutant was intracellularly retained, similar to the 
C251 → F mutant.
The effects of the last two extracellular mutations (S256 →  F 
and H170 → L) are harder to explain. Alignment of MCR coding 
sequences reveals that residue S256 is somewhat conserved (present 
in three out of five human MCRs), while the model suggests that 
the side chain of MC4R-S282 (ACTHR-S256) is oriented toward the 
external surface of the receptor and thus cannot directly interact 
with the ligand. However, it is located adjacent to MC4R-M281 
(ACTHR-M255) that lines the binding cavity, and in close prox-
imity to the disulfide bond forming MC4R-C279 (ACTHR-C253). 
Thus, replacement of the small, polar, and hydrophilic S with a 
bulky, non-polar, and hydrophobic F could affect these function-
ally important residues by misfolding the extracellular region, 
resulting in the retention of the receptor in the interior of the cell. 
The mechanisms of this effect may vary; for example, to minimize 
contact with water molecules, the side chain of F could reorient 
from the exterior surface to the internal cavity of the receptor, 
or as predicted by TMpred software (186), increase the length 
of TM7 by introducing an additional turn so that it is embedded 
within the lipid bilayer of the membrane.
Although difficult to explain, the H170 → L variant is perhaps 
the most interesting mutation of on the extracellular side of 
ACTHR because it is located within EL2, which is the shortest 
of the three loops. In most MCRs, this region is well conserved 
and formed from one acidic residue (E or D) and a number of 
hydrophilic and/or polar residues (Figure 4), but within ACTHR 
there are two basic H and one hydrophilic S residue. The conser-
vation of acidic residues and the participation of both flanking 
residues in the formation of the binding cavity of MC4R are 
indicative of a functional purpose. Perhaps it works as “bait” for 
basic residues on the MC pharmacophore to recruit/direct ligand 
to the cavity entrance. Alternatively, it could interact with the 
basic –K–K–R–R–P– motif of ACTH, thus modulating its recep-
tor activation ability. Determination of the true purpose clearly 
requires additional research. Nevertheless, such speculation is at 
least partially untrue in the case of ACTHR because the basic 
H170 is in the exact position occupied by an acidic residue in other 
MCRs, yet the loss of functional activity observed by Clark’s group 
(156) shows that it is still important. Peculiarly, the Clark group 
also observed that H170 → L, D103 → N, D107 → N, and R128 → C 
were the only 4 out of 22 functionally hampered receptors that 
were effectively transported to the cell membrane. Unifying the 
other three mutations was their location and functional purpose, 
since all are located deep within the cavities of ACTHR, and all 
participate in ligand–receptor or receptor–G-protein interac-
tions. Thus, it can be presumed that these substitutions altered 
only the internal surface and not the overall structure of ACTHR. 
In light of this knowledge, it is tempting to speculate that H170 → L 
could have similar effects. However, being located on the edge of a 
binding cavity, this residue cannot participate in interactions with 
the MC consensus pharmacophore and must instead interact 
with either the second ACTH pharmacophore (–K–K–R–R–P–) 
or with MRAP1.
According to the MC4R model, mutations in the central part 
of the TM domains are located either on the external surface 
of ACTHR and thus in contact with the lipid bilayer (S74 →  I 
T152 → K, T159 → K, and G226 → R) or buried within the tightly 
packed core of the TM bundle (S120 → R and G116 → V). Therefore, 
it was not surprising that all native residues were small and/or 
hydrophobic, and mutated residues were hydrophilic (S120 → R, 
T152 → K, T159 → K, and G226 → R) or significantly larger than 
native residues (S74 → I and G116 → V). The mechanisms underly-
ing the changes in receptor activity for all these substitutions thus 
appear to be very simple. In the case of hydrophobic → hydro-
philic alterations, the introduced residue would likely induce a 
rotational shift of the TM domain to minimize exposure to the 
hydrophobic environment, while for small →  large alterations, 
the surrounding structure would have to shift to accommodate 
the larger residue. Either type of rearrangement would likely 
result in misfolding and/or altered functional cavities.
Analogous to mutations located on the extracellular side of 
receptor, those on the intracellular side likely affect receptor–G-
protein interactions. The crystal structure of the β2 adrenergic 
receptor–Gs protein complex identified a number of receptor 
residues that are involved in interactions between both partners 
(163). Although the β2 adrenergic receptor (ADRB2) and ACTHR 
are relatively distantly related (~26% sequence identity), they 
both couple with the Gαs subunit, thus the ACTHR surface that 
interacts with Gα should be similarly folded to that of ADRB2 
(Figure 6). For this very reason, we based our subsequent analysis 
described in the next paragraphs on this receptor–ligand complex 
crystal structure (PDB ID: 3SN6).
Given that there are a significantly larger number of GPCR 
subtypes than G-protein subtypes, the correct folding of the intra-
cellular parts of receptors is presumably rigorously monitored 
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and misfolded molecules intracellularly retained and degraded. 
Indeed, this was observed by the Clark group (156) who char-
acterized a number of intracellular mutations located within 
ACTHR regions that either directly interact with Gαs (R128 → C) 
or are homologous to residues that form the surface of ADRB2 
Gαs coupling cavity (L55 → P, H139 → Y, V142 → L, P281 → fs, and 
K289 → fs). The effect of R128 → C can be easily explained because 
it is located within the highly conserved rhodopsin GPCR family 
–D–R–Y– motif, which is involved in signal transduction. The 
retention of L55 → P, H139 → Y, and V142 → L is most probably 
caused by relevant changes in the properties of the residues. 
Mutation to P often restricts the backbone of the polypeptide 
chain and prevents the adoption of its native conformation, 
while the replacement of more hydrophilic H and V to more 
hydrophobic Y and L generally causes local structural rearrange-
ments because the introduced residues tend to get buried deeper 
within the protein or lipid bilayer to minimize contact with water 
molecules. In the case of V142, these local rearrangements and the 
increased size of the hydrophobic side chain could possibly affect 
phosphorylation of the adjacent T143 because the homologous 
position (T157) within MC1R is critical for receptor functional 
activity (86, 187, 188). Peculiar, however, were the P281 and K289 
frameshifts and the M290  →  Stop mutation affecting located 
within the small C-terminal intracellular α-helix (often referred 
as H8). Since neither structural data nor experimental results 
have illuminated the role of this region in signal transduction via 
G-protein binding, the retention caused by its loss seems interest-
ing. Several research groups have undertaken efforts to uncover 
the purpose of this structural element, but results are ambiguous 
(189–191). Its primary role could be to properly orient the GPCR 
within the plasma membrane, so that it can be effectively accessed 
by both ligand and G-protein.
Results from mutations located outside the binding cavity are 
harder to interpret, yet some appear relatively straightforward. 
Substitution of Y129 → C, located within the previously mentioned 
–D–R–Y– motif, can be interpreted based on the ADRB2 struc-
ture, which suggests this particular residue is oriented toward 
the exterior of the molecule, and a role in signal transduction 
has been demonstrated in other MCRs (192). The A126 → S and 
I130 →  N replacements involve changes from hydrophobic to 
hydrophilic residues. In both cases, the side chains of native resi-
dues are predicted to be located on the surface of the receptor and 
oriented toward the lipid bilayer; therefore, these replacements 
most probably induce some structural rearrangements so that 
the mutated residues have limited interaction with the hydro-
phobic environment of the membrane. The opposite is likely 
true of R137 → W, in which the hydrophilic R is replaced with 
the hydrophobic W. R137 (ADRB2-K140) is located between Y138 
(ADRB2-Y141), and L136 (ADRB2-F139), and the first of these two 
residues interacts with D in the –D–R–Y– motif that orients the 
second residue toward the hydrophobic pocket of the G-protein. 
It appears the purpose of the basic R137 is to serve as a kind of 
a “lever” that keeps this otherwise hydrophobic region at the 
surface of the cell membrane. Its replacement would likely cause 
this region to adopt a different conformation and possibly “sink” 
deeper in to the membrane. As already mentioned, replacements 
involving P are often associated with large changes in the protein 
backbone, and this appears to be the case for P273 →  H and 
L198 → P. P273 (ADRB2-P323) is one of the most highly conserved 
residues within rhodopsin GPCRs, where it introduces a kink 
in TM7 that allows the highly conserved Y276 (ADRB2-Y326) to 
interact with Gαs. Introduction of H at this position would likely 
disrupt the native conformation. The opposite is true of L198 which 
is located at the base of TM5 and followed by IL3, which plays a 
crucial role in receptor–G-protein interactions. Introduction of 
P and an associated α-helical kink would alter the orientation of 
the entire loop, resulting in a misfolded receptor with hampered 
signal transduction ability.
Of all the intracellular mutations, the effects of V49  →  M 
and R146 → H are hardest to interpret, because in both cases the 
native residue is replaced with a residue that has similar proper-
ties. Nevertheless, closer examination involving analysis of the 
ADRB2 structure can shed light on the underlying mechanisms. 
Replacement of V49 → M involves only a change in size and the 
introduction of a sulfur atom. V49 (ADRB2-I58) is located on the 
surface at the base of TM1 and being hydrophobic, it does not 
protrude outwards but is instead oriented along the surface of 
the ACTHR molecule toward the TM2 domain and the receptor 
interior. V is a small residue compared with M, therefore the size 
difference could account for the observed effects. However, in 
ADRB2, the same position is occupied by I, which is also larger 
than V, yet this receptor has high activity, indicating that the 
introduction of a sulfur atom cannot be excluded. Interestingly, 
both sulfur-containing residues (C and M) and H are able to 
bind metal ions, and if several similar residues are present in a 
given location, they may simultaneously bind single metal ion to 
form a bridge-like structure. According to the crystal structure 
of ADRB2, the base of both TM1 and TM2 is located in close 
proximity, and there is an additional M59 at the base of the TM2 
domain in ACTHR that may be sufficiently close to form a 
metal-binding site with the mutated M49 (V49 → M). Based on the 
structural similarity with ADRB2, this second M59 (ADRB2-T68) 
is likely located within the functionally important region that 
interacts with the previously mentioned Y138 (ADRB2-Y141) and 
D127 (ADRB2-D130) from the –D–R–Y– motif, hence the forma-
tion of this putative metal bridge-like structure could alter the 
ability of the receptor to activate the G-protein. Although this 
theory seems highly speculative, in our previous studies, we suc-
cessfully introduced similar albeit artificial metal-binding sites 
into the structure of MC4R (147).
The R146 →  H replacement involves residues that both are 
basic, suggesting the observed decrease in receptor’s ability 
to bind ligand, induce functional response and reach cellular 
surface is due to size differences, aromatic interactions, or the 
ability to bind metal ions rather than the loss of a reactive group. 
R146 (ADRB2-K149) is located on the surface of the receptor at 
the base of the TM4 domain. Being hydrophilic, this residue 
is oriented toward the surface of the molecule, thus structural 
alterations due to size differences are unlikely to affect receptor 
function. Coincidentally, as with the TM1 domain, the base of 
this domain is also located in close proximity to the TM2 domain. 
Therefore, the formation of a M59–H146 metal-binding pocket 
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that alters the conformation of the intracellular region is also 
plausible. Additionally, within the TM2 domain, approximately 
one α-helical turn above M59 is located F62 (ADRB2-F71), which 
is conserved in rhodopsin GPCRs. The side chain of this residue 
is oriented toward the TM4 domain, suggesting that abnormal 
aromatic interactions could prohibit ACTHR from adopting its 
native conformation in a similar way to that proposed for the 
putative metal-binding pockets described above.
In addition to mutations that hamper receptor activity, the 
intracellular part of ACTHR includes two constitutive activity 
mutations F278 → C and the double mutation C21 → R + S247 → G. 
The first of these mutations was discovered in a patient with 
ACTH-independent Cushing’s syndrome, a disease typically 
caused by excess ACTH. Functional analysis revealed that this 
mutated receptor was effectively transported to the cell surface 
and displayed functional activity parameters that were compa-
rable with WT ACTHR. The only difference was the elevated 
basal activity. Further research revealed that this effect was due 
to deficient receptor desensitization, and site-directed mutation 
of the phosphorylation site in the S280 →  A variant resulted in 
a receptor with similar properties (109). The authors of this 
article concluded that the F278 → C mutation somehow masks the 
presence of the phosphorylation site. However, the mechanism 
of this masking is still unknown and hard to interpret. Some 
years later, a patient was identified that in addition to F278 → C 
also carried an inactivating Y129 → C mutation (as described in 
previous paragraphs). As a result, this double mutant receptor 
was intracellularly retained.
Although considered to be rare, this C21 → R + S247 → G double 
mutant was identified in another ACTH hypersensitivity patient 
(164). However, unlike in the previous patient, this mutant 
displayed only basal activity, and cAMP accumulation was not 
observed upon stimulation with ACTH. Expressed separately, 
both mutations generated functionally inactive receptors (as 
described in previous paragraphs), thus the authors speculated 
that within the double mutant these residues are located in close 
proximity and are required to maintain the receptor in an acti-
vated conformation.
Taken together, the knowledge gained from naturally occurring 
mutations is in good agreement with the findings of Pogozheva 
et  al. (148), the MC4R-binding pocket model, and the crystal 
structure of the β2 adrenergic receptor–Gs protein complex of 
Rasmussen et al. (163). Thus, both models appear to be useful 
for evaluation of the effects caused by single residue mutations.
SiTe-DiReCTeD MUTAgeNeSiS
Although analysis of naturally occurring mutations has 
provided us with a significant amount of functional data, the 
nature of this type of research can be somewhat random and 
unfocused. Thus, in order to pursue a broader knowledge on 
ACTHR specificity and the underlying molecular mechanisms, 
several research groups employed site-directed mutagenesis and 
subsequent functional characterization of mutated ACTHRs. 
Due to the difficulties to express functionally active ACTHR 
(193), majority of such studies were performed only after the 
characterization of Y6 and OS3 adrenal cell lines (106) and/or 
discovery of MRAP1 (39).
One of the first to perform systematic mutagenesis of 
ACTHR was Yang and colleagues who had already performed 
similar analyses on other MCRs (138, 139, 142). They intro-
duced 16 point mutations within various ACTHR regions 
to assess their functional role in ligand binding and receptor 
activation. The  repertoire of mutations covered both residues 
that were known to alter the activity of MC1-3R, and residues 
that, according to sequence alignment, were unique to ACTHR. 
The results of these analyses are summarized in Table 3 (146). 
In Section “Discussion,” the authors concluded that the general 
organization of the ACTHR ligand-binding cavity is similar to 
that of other MCRs, as it also consists of acidic- and aromatic-
binding pockets formed by the same “backbone” residues (E80, 
D103, D107, F235, and H238). However, there are also significant 
differences. Compared with other MCRs, the role of D103 in 
ligand binding and receptor activation is significantly dimin-
ished, as its alteration caused only a 2.8-fold decrease in ACTH 
(1–24) affinity and a 7.3-fold decrease in potency. The role of 
this residue appears to be compensated by the adjacent D104 that 
is unique to ACTHR, since replacement of this residue had a 
greater effect (10.2-fold and 18.3-fold decrease, respectively). 
A number of aromatic residues unique to ACTHR were also 
tested, and their replacement with alanine had a significant 
(F168) or even tremendous (F110 and F178) effect on ligand binding 
and receptor activation. This led to speculation that the binding 
cavity of ACTHR could be “broader” than that of other MCRs 
and could accommodate additional ligand residues that would 
interact with some of the identified functionally relevant unique 
residues (146). However, work based on the MC4R-binding 
pocket model (148) partially counters this speculation, because 
homologous positions of these high effect aromatic residues 
(F110 and F178) were located in close proximity to aromatic 
residues of the MC consensus pharmacophore (F235 and W232, 
respectively), thus indicating their role in ligand binding and 
receptor activation. Nevertheless, this “broader” binding cavity 
remained possible because homologous position of the basic 
ACTHR-K77 within MC4R model resides within the densely 
packed and hydrophobic TM domain bundle region adjacent to 
the acidic D103. Being charged and larger than N (in MC1, MC3, 
and MC4R) or S (in MC5R), this residue could conceivably 
thread through this region toward the surface of the binding 
cavity and interact with D103 to alter (broaden) the cavity. In 
light of the previously discussed naturally occurring H170 → L 
mutation is was particularly interesting to test F168 which, like 
H170, is located within EL2 at the entrance to the binding cavity, 
and, like H170, it affects ligand binding, although apparently to a 
lesser extent. This provided further evidence of the role of this 
region in receptor functional activity.
Although very informative, this work by Yang and colleagues 
was not their first involving ACTHR. In their preceding study 
(published only a few months earlier), they used chimeric MC4/
ACTHR receptors to probe TM domain residues of MC4R that 
are responsible for the high affinity for the synthetic ligand NDP-
MSH (195). Due to the high ligand recognition specificity, they 
TAble 3 | Site-directed mutants of adrenocorticotropic hormone receptor (ACTHR) and their effects on receptor function.
Mutation binding 
(×wtACTHR)
Cyclic adenosine 3′,5′-monophosphate 
(×wtACTHR)
Membrane trafficking 
(×wtACTHR)
Rate of internalization  
(% of initial rate)
Reference
D70 → A X X X (146)
*K77 → A Ki = 4.5×↑ EC50 = 7.8×↑ 1.4×↓
E80 → A Ki = 11.6×↑ EC50 = 9.8×↑ 1.3×↓
*N81 → A Ki = 1.8×↑ EC50 = 2.4×↑ 1.1×↓
D103 → N Ki = 2.8×↑ EC50 = 7.3×↑ 1.5×↓
*D104 → N Ki = 10.2×↑ EC50 = 18.3×↑ 1.3×↓
D107 → N Ki > 178.6×↑ EC50 > 1250.0×↑ 1.5×↓
*F110 → A Ki > 116.3×↑ EC50 > 208.3×↑ 1.5×↓
*T164 → A Ki = 1.2×↓ EC50 = 1.3×↓ 1.1×↓
*F168 → A Ki = 25.3×↑ EC50 = 68.3×↑ 1.8×↓
*F178 → A Ki > 178.6×↑ EC50 > 1250.0×↑ 1.5×↓
F235 → A Ki = 17.5×↑ EC50 = 270.0×↑ 1.2×↓
H238 → A Ki > 178.6×↑ EC50 > 1250.0×↑ 1.4×↓
*F244 → A Ki = 1×↔ EC50 = 1.1×↑ 1.1×↓
F258 → A Ki = 13.9×↑ EC50 = 233.8×↑ 1.3×↓
D272 → A X X X
N12N13 → QQ EC50 = ~1.4×↑ ↔ (194)
N17N18 → QQ EC50 = ~2.1×↑ ↔
N12N13N17N18 → QQQQ EC50 = ~4.5×↑ ~3.2×↓
wtACTHR Rmax = 1×↔ 1×↔ 33.1 (86)
T131 → A Rmax = 1.1×↓ 1.27×↑ <0.1
T131 → D Rmax = 4.5×↓ 1.3×↑ <0.1
S140 → A Rmax = 1.1×↓ 1.1×↓ 25.5
S140 → D Rmax = 1.2×↓ 1.25×↑ 43.2
T143 → A Rmax = 33.3×↓ 100×↓ 22.2
T143 → D Rmax = 1×↔ 3.1×↓ 16.3
T143 → S Rmax = 1.1×↑ 2.3×↓ 27.7
T143 → G X 11.1x↓ X
T143 → K Rmax = 2.9×↓ 12.5×↓ X
T147 → A Rmax = 1.2×↑ 1.2×↑ 23.6
T147 → D Rmax = > 100×↓ >100×↓ <0.1
S202 → A Rmax = 1×↔ 1.5×↑ 40.6
S202 → D Rmax = 1.1×↑ 1.1×↓ 60.7
S204 → A Rmax = 1.2×↑ 1×↔ 18.8
S204 → D Rmax = 1×↔ 1.5×↓ 39.4
S208 → A Rmax = 1.1×↑ 1.1×↓ 22.6
S208 → D Rmax = 1.1×↓ 1.1×↓ 56.7
T209 → A Rmax = 1.1×↑ 1×↔ 32.4
T209 → D Rmax = 1.1×↓ 1.2×↓ 20.1
S280 → A Rmax = 1×↔ 1.4×↓ 50.8
S280 → D Rmax = 1.5×↓ 1.1×↓ <0.1
S294 → A Rmax = 1×↔ 1.3×↓ 36.4
S294 → D Rmax = 1.4×↓ 1.3×↓ 49.0
N12N13N17N18 → QQQQ Rmax = 1.2×↓ 3.0×↓ 80.5
×, fold difference compared with wtACTHR; ↔, value unaffected; ↑, value increased; ↓, value decreased; X, not determined; empty field, no data available.
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intended to use the TM domains of ACTHR for loss of function 
studies, and in order to localize the alterations and simplify data 
interpretation, they replaced only one TM domain (TM2, TM3, 
TM4, TM5, or TM6) at a time without disruption of adjacent 
intracellular or ELs. The results revealed that in majority of 
cases these replacements had little or no effect on receptor sur-
face expression, NDP-MSH recognition or receptor activation 
efficiency. The exception was the replacement of TM3 (hMC4R/
TM3 hMC2R); although this receptor was transported to the 
cell surface, it displayed significantly reduced ligand affinity and 
potency (a 12.7-fold and 40-fold decrease, respectively; Table S1 
in Supplementary Material). Therefore, the authors concluded 
that non-conserved residues in this region determine the ability 
of MC4R to effectively bind NDP-MSH (195). However, based 
on the above knowledge, we believe that these observations are 
more likely due to peculiarities of ligand recognition within 
ACTHR rather than MC4R, in particular binding pocket dis-
turbance caused by the presence of an additional acidic (D104) 
residue, and also possibly the aromatic F110 residue (195).
The successful application of a chimeric receptor strategy 
for various MCRs has been reported on multiple occasions 
(195–198). Since this initial work number of groups including 
our own group has used this platform for functional research on 
ACTHR (199–202). However, since the results of these studies are 
to a degree speculative, and because different analytical methods 
were employed, the findings are quite difficult to summarize and 
so are reviewed in chronological order.
Although many groups were working in parallel, we were 
the first group to publish in this area. During the initial stages 
of our research (199), we were more interested in exploring the 
structural elements that determine the selectivity of ACTHR 
membrane expression rather than its ligand recognition selectiv-
ity. Therefore, since it was already known that posttranslational 
modification of the N-terminus affected the membrane transport 
of cell-surface glycoproteins, in our first set of chimeric recep-
tors, we substituted this region in both ACTHR and MC4R. 
The results partially confirmed our hypothesis; the membrane 
expression of MC4R with the ACTHR N-terminus (Ch1 in 
Table S1 in Supplementary Material) was significantly reduced 
compared with wt MC4R. The results also demonstrated that the 
N-terminus is not the only region of ACTHR that facilitates its 
intracellular retention, because ACTHR with the N-terminus 
of MC4R (Ch2 in Table S1 in Supplementary Material) was 
not trafficked to the cell membrane. Thus, to explore further, 
we created additional sets of chimeric receptors by replacing 
ACTHR TM domains with corresponding regions of MC4R in 
various combinations (Ch3–Ch15 in Table S1 in Supplementary 
Material). Subsequent evaluation of the membrane transporta-
tion efficiency revealed that retention occurred only when both 
TM3 and TM4 from ACTHR were present simultaneously, 
suggesting this region, or elements of this region, is responsible 
for intracellular retention. In addition to membrane transporta-
tion, we also carried out binding and cAMP response analyses. 
Although, due to their sensitivity, the initial purpose of these 
assays was to enable the detection of low-level membrane traf-
ficking, the results also identified regions that determine ACTHR 
ligand-binding specificity. MC4R-based chimeric receptors were 
able to bind ligands when TM4–5 and TM6–7 were replaced 
with the corresponding parts of ACTHR, but binding was not 
observed when both regions were replaced simultaneously. 
Thus, we speculated that there must be some kind of interaction 
between these two elements, which disrupts the conformation 
required for formation of the MC consensus pharmacophore 
(M–X–H–F–R–W) binding pocket (199).
A year after publication of our report, Hinkle and colleagues 
reported on employment of remarkably similar strategy (201). 
Indeed, several of the chimeric receptors were identical in spite 
of being independently created. However, they employed distinct 
methods for characterization of the chimeric receptor properties 
(i.e., measurement of surface transport and activation efficiency), 
and they also evaluated the effects of co-expression with MRAP1. 
As in our study, the chimeric receptors were generated in sets. 
The first set included ACTHR-based chimeric receptors with a 
variety of TM domains replaced to corresponding regions from 
MC4R (2C1–2C6 in Table S1 in Supplementary Material), while 
the second set mirrored these so that the same TM domains 
within MC4R were replaced with the corresponding regions 
from ACTHR (4C1–4C6 in Table S1 in Supplementary Material). 
Functional analysis confirmed that co-expression with MRAP1 
promoted the cell-surface trafficking of ACTHR-based chimeric 
receptors, but this was decreased with MC4R-based receptors. 
However, the ACTHR-based receptor with only the N-terminus, 
TM1 domain, and IL1 replaced to the corresponding regions 
of MC4R (2C1 in Table S1 in Supplementary Material) was an 
exception, since it was located on the cell surface even in the 
absence of MRAP1, but despite its successful transportation it 
was functionally inactive. To investigate this further, Hinkle and 
colleagues created an additional set of chimeric receptors (C2C1a, 
C2C1b, and C2C1c in Table S1 in Supplementary Material), and 
subsequent evaluation of their properties narrowed the region 
responsible for intracellular retention to TM1 alone, because 
the corresponding receptor variant (C2C1b in Table S1 in 
Supplementary Material) was both effectively transported to the 
cell plasma membrane, and functionally active in the presence of 
MRAP1. Functional analysis of receptors from the main set also 
revealed another surprising discovery; when co-expressed with 
MRAP1, ACTHR-based chimeric receptor with TM2, EL1, and 
TM3 replaced to the corresponding regions of MC4R (2C2 in 
Table S1 in Supplementary Material) was able to induce intra-
cellular response upon stimulation with both NDP-MSH and 
ACTH and also displayed substantial constitutive activity. Since 
both of these traits are known to be characteristic of MC4R, the 
authors attempted to pinpoint the responsible region by under-
taking the creation of another set of C2C2 derivative chimeric 
receptors (C2C2a, C2C2b, C2C2c, and C2C2d in Table S1 in 
Supplementary Material), but functional data showed that none 
shared the properties of the parental chimeric or wt receptors. 
Based on this and other studies, Hinkle and colleagues proposed 
that a more likely explanation for these observations was the 
general misfolding of ACTHR that, without the assistance of 
MRAP1, is unable to pass the rigorous quality control system in 
the ER and is subsequently degraded. Regarding our article, the 
FigURe 7 | Cartoon representation of the crystal structure of bovine 
rhodopsin (150). EL2 (magenta) forms a lid-like structure over the 
ligand-binding pocket that prevents any external molecular interference with 
the covalently bound ligand.
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authors simply remarked that although they did not study exactly 
the same chimeras, but according to their data introduction of the 
TM2–TM3 or TM4–TM5 regions of ACTHR receptor had little 
effect on MC4R surface expression (201).
Based on confidence in our own results and given that the 
action of ACTHR remained largely unexplained, we decided to 
further investigate the matter. In our following study (200), we 
generated additional sets of ACTHR-based chimerical receptors. 
Given our previously proposed hypothesis that the N-terminus 
and TM3–TM5 region of ACTHR was important for receptor 
transportation and ligand recognition specificity, we replaced 
various elements of these regions with the corresponding ele-
ments of MC4R (Ch16–Ch22 in Table S1 in Supplementary 
Material). Similarly to the Hinkle group, we tested all receptors 
for their ability to reach the cell plasma membrane and induce 
intracellular cAMP responses upon stimulation with ACTH and 
α-MSH during both standalone expression and co-expression 
with MRAP. The results were somewhat unexpected because they 
indicated that the integrity of the extracellular part of receptor 
and not the separate TM domains was of paramount importance 
for the formation of ACTHR-specific and MRAP1-dependent 
arrest signal. Although initially these observations seemed to 
conflict with the conclusions of our former publication, in-depth 
reanalysis of data from both studies revealed a good agreement. 
In most cases, when the N-terminus, EL1 and EL2 of ACTHR 
were present the chimera was retained, but when two of the 
three elements were present, transport of the chimera to the 
membrane was hampered (Table S1 in Supplementary Material). 
Intrigued by this finding, we decided to verify and investigate it 
in more detail by making smaller (two to five aa) replacements 
within the TM3–TM5 region of Ch2, a chimera from our previ-
ous study, which is essentially ACTHR with the N-terminus of 
MC4R (Table S1 in Supplementary Material). While performing 
the same analyses as carried out on previous sets of receptors, 
we observed that in most cases these replacements increased the 
membrane export efficiency during standalone expression, but 
replacement of residues located within the central part of TM3 
and the intracellular part of TM4 had no effect (Ch24, Ch27, and 
Ch28 in Figure S1 in Supplementary Material). Co-expression 
with MRAP1 revealed a whole spectrum of effects, including 
receptors that were unaffected by MRAP1 and still retained 
(Ch28 in Figure S1 in Supplementary Material), receptors unaf-
fected by MRAP1 and still effectively transported to the mem-
brane (Ch26, Ch32, and Ch35 in Figure S1 in Supplementary 
Material), receptors with improved transportation efficiency 
comparable with ACTHR (Ch24, Ch27, Ch30, Ch31, and Ch34 
in Figure S1 in Supplementary Material), and receptors with 
decreased transportation efficiency comparable to MC4R (Ch23, 
Ch25, Ch29, and Ch33 in Figure S1 in Supplementary Material). 
As observed with large-scale replacements, these results were 
unexpected because we believed we finally understood ACTHR 
specificity. Nevertheless, like Hinkle and colleagues, we came 
to the conclusion that the overall structure of ACTHR must 
be somewhat attuned for misfolding as changes within various 
regions could avert this effect. Thus, we speculated that similarly 
to bovine rhodopsin, the extracellular part of ACTHR might form 
a lid-like structure over the ligand-binding pocket (Figure  7), 
but rather than being permanent like in rhodopsin, it must be 
able to undergo MRAP1- and –K–K–R–R–P– pharmacophore-
induced conformational changes that result in opening of the 
–M–X–H–F–R–W– binding cavity. In addition, this lid-like 
structure could also serve as an arrest signal, since being located 
on the surface of the cell membrane, it is readily accessible to 
components of the ER quality control system. However, it also 
appeared that the correct formation of this structure requires 
a precise alignment of the TM domains, as even the slight-
est changes were able to disrupt its formation. Although this 
study, like the previous one, mainly focused on identification of 
mechanisms underlying the ACTHR membrane transportation 
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specificity, we were also able to gain some insight regarding 
structures that determine its ligand recognition specificity. Since 
all chimeric receptors created during this study were ACTHR 
based, it was not surprising that the majority of them were able 
to induce cAMP responses only when co-expressed with MRAP1 
and stimulated with ACTH; therefore, the most interesting in this 
respect were the functionally inactive Ch24 and Ch31 (Figure S1 
in Supplementary Material). The functional inactivity of Ch24 
was rather easy to explain, since all affected residues were located 
in close proximity to residues known to form the –M–X–H–F–
R–W– acidic-binding pocket. However, residues replaced within 
Ch31 were far more interesting because they are located within 
EL2 that forms the edge of the binding cavity, as described above 
regarding the naturally occurring H170 → L mutation. Since none 
of the adjacent alterations displayed a similar effect, and because 
selected residues were substituted with corresponding ones from 
MC4R, we concluded that this region must be either involved 
in the formation of the –K–K–R–R– binding pocket or func-
tional interaction between ACTHR and MRAP1 that mediates 
receptor activation. In an attempt to explain this observation, 
we also compared the properties of the original and substituted 
residues, which showed that H170 and H171 (substituted with D 
and S, respectively) were the most plausible candidates for resi-
dues with a functional role because their replacement had the 
most significant effect on properties of this region, and due to 
its potential positive charge, propensity for hydrogen-bonding, 
and aromatic nature, histidine is often a functionally important 
residue (200).
The latest in a series of publications on chimeric ACTH/MC4 
receptors was published by Yang and colleagues (202). This study 
assessed the binding affinity and potency of the synthetic ligand 
[d-Phe7]ACTH(1–24) on chimera receptors that were very 
similar to those described in their previous report in 2007 (195) 
(Table S1 in Supplementary Material). Their main conclusion 
was also very similar to their former conclusion that TM3 of 
ACTHR is critical for ligand selectivity and potency. Therefore, 
due to their lack of novelty, these results are not reviewed in 
detail, although there is one aspect that must be mentioned. 
In this article, the authors also described the creation of five 
ACTHR-based receptors with single TM domain substitutions 
to corresponding regions of MC4R (TM2, TM3, TM4, TM5, or 
TM6; Table S1 in Supplementary Material). In the experimental 
procedures section, the authors indicated that expression of chi-
meric receptors was performed in both OS3 and HEK cell lines, 
the former of which is known to support functional expression 
of ACTHR. However, during the experiments, they observed 
that all ACTHR-based chimeric receptors were transported to 
the cell surface at very low levels, and they therefore failed to 
assess their ligand-binding affinity and potency (202). Although 
co-expression with MRAP1 in HEK293 or CHO cell lines and 
the OS3 cell line may not be directly comparable, in our view, 
these results are somewhat contrary to the observation made by 
us and the Hinkle group that most ACTHR-based chimeras co-
expressed of with MRAP1 were able to reach the cell membrane 
and many were functionally active.
Interpreting the results of studies using ACTH/MC4 chimera 
receptors can be difficult and even controversial. We believe this 
is due to using a small-scale approach such as few chimeric recep-
tors with single domain replacements to investigate large-scale 
problems such as the molecular structure and intermolecular 
interactions of ACTHR (i.e., overinterpretation of results acquired 
using the reductionist approach). This could be compared with 
observing the construction of a building through small holes 
in the fence that surrounds it. Since each group generates their 
own hypotheses and is only able to generate and test a limited 
number of mutant receptors, they see only a small part of the 
“bigger picture” and thus were viewing the problems from a dif-
ferent perspective. Nevertheless, in spite of these differences, we 
have attempted to summarize the disparate results in Table S1 in 
Supplementary Material, and, to our surprise, data obtained by 
different groups are generally in good agreement. Of course, some 
seemingly identical receptors displayed very different properties 
in the hands of different research groups, and differences in the 
expression systems may account for the apparent discrepancies 
(for example, Ch5 or Ch6 in our study and 2C6 or 4C4 in the 
Hinkle group). However, the overall general agreement allowed 
us to draw some summative conclusions. Firstly, it appears there 
is no single domain that is responsible for ACTHR intracellular 
retention, but rather the general structure of ACTHR may be 
somewhat misfolded and coupling with MRAP1 is required to 
either correct or mask this. Secondly, the results indicated that the 
role of the extracellular and possibly even the intracellular parts 
of ACTHR had been underestimated, because in multiple cases 
the substitution of even a single loop or terminus was crucial on 
determining receptor localization and the ability to induce an 
intracellular response.
While ourselves and others were working on large-scale replace-
ments and searching for domains and regions that determine the 
membrane transportation and ligand recognition specificity of 
ACTHR, a group led by Gallo-Payet was taking a more focused 
approach on ACTHR glycosylation (194) and phosphorylation 
(86) and their effects on receptor functionality. These simple, 
elegant studies are reviewed below, again in chronological order.
It has been known for quite some time that glycosylation of 
cell-surface proteins is often required for their successful trans-
port to the plasma membrane (203, 204). In the case of GPCRs, 
however, the effects of glycosylation are wider and range from 
being important for correct receptor folding and maturation, to 
having no apparent function (205–208). Prediction of potential 
glycosylation sites within ACTHR using such online tools as 
NetNGlyc 1.0 Server1 or GlycoEP2 identifies two glycosylation 
sites within the N-terminus of the receptor: N12N13T14 and 
N17N18S19 (Figure 6). Since this aspect of ACTHR functionality 
had not been previously researched in detail, Roy et  al. (194) 
employed site-directed mutagenesis to eliminate these sites and 
performed functional expression and characterization of the 
resultant mutated ACTHRs within the HEK293/FRT cell line 
to evaluate the role of glycosylation. Upon first reading, the 
results of this study seemed rather confusing, as the authors 
observed that during standalone expression abolishment of one 
1 http://www.cbs.dtu.dk/services/NetNGlyc/.
2 http://www.imtech.res.in/raghava/glycoep/.
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glycosylation site had a moderate effect on the surface trans-
portation of ACTHR, while abolishment of both significantly 
reduced it. In addition, co-expression with MRAP1 (α, β, or 
C-terminally truncated) resulted in the effective rescue of surface 
expression for mutants with only one valid glycosylation site, 
and moderate rescue for mutants with no glycosylation sites 
(Table  3). The confusing part, of course, was the presence of 
ACTHR at the cell membrane in the absence MRAP. However, 
this was later explained by the discovery that this cell line actually 
expresses low levels of MRAP2 that promotes ACTHR membrane 
transportation. Although at the first glance the selection of this 
expression system might seem unfortunate, it actually allowed 
the researchers to observe the effects of glycosylation in detail 
because, due to overexpression and MRAP1 rescue effects, the 
employment of any other MRAP2-less cell line most probably 
would not have allowed them to distinguish between unham-
pered and moderately hampered transportation efficiency. The 
causal reason for the endogenous expression of this accessory 
protein could be related to the source of the particular human 
embryonic kidney cell line. Based on MRAP2 expression data 
available at “The Human Protein Atlas”3 (209, 210), adult kidney 
tissue expresses this protein at low levels. Although the same 
database suggests the parent (HEK293) cell line does not express 
this protein, it is plausible that this cell line is prone to triggering 
expression during later passages, hence its use in ACTHR surface 
expression studies should be carefully considered. In addition 
to cell-surface transportation measurements, the authors also 
performed receptor activation experiments, and all mutated 
receptors were functionally active, but there was a tendency for 
EC50 values to increase with the number of mutated glycosylation 
sites, thus it was concluded that N-glycosylation of ACTHR is 
not critical but does have a slight influence on receptor activity 
(Table 3) (194).
Another type of posttranslational modification that often 
plays a major role in protein functionality is phosphorylation. 
In the case of GPCRs, it is usually associated with receptor desen-
sitization and internalization, and it is performed by a group of 
serine/threonine protein kinases known as G-protein-coupled 
receptor kinases (211–215). Since this aspect of ACTHR action 
was not previously researched in detail, Roy and coworkers (86) 
introduced point mutations that altered all S and T residues 
located within the intracellular part of the receptor to the 
non-phosphorylatable residue A, or to the negatively charged 
D that can mimic phosphorylation. Additionally, T143 was also 
mutated to S, G, and K because, as already mentioned above, 
the homologous position (T157) within MC1R is critical for 
receptor export to the plasma membrane and thus functional 
activity (86, 187, 188). Detailed activation, surface expression, 
and receptor internalization analyses both standalone and dur-
ing co-expression with MRAP1β in the HEK293/FRT cell line 
generated a large number of results, the most relevant of which 
(in the context of this review) are presented in Table  3. The 
authors initially evaluated the internalization of WT ACTHR 
3 http://www.proteinatlas.org/.
and established that ligand binding is a necessary prerequisite 
for ACTHR internalization. Additionally, MRAP1 was internal-
ized along with ACTHR, further confirming that a functional 
receptor is formed following the formation of ACTHR and 
MRAP1 complex. They also revealed that stimulation with low 
concentrations of ACTH (<0.3 nM) did not induce any apparent 
internalization, and ~28% of internalized receptor molecules 
were recycled back to the cell surface. Having established a 
baseline and confirmed the necessity of further investigations 
on the role of intracellular S/T residues, Roy et al. (86) carried 
out similar analyses on all mutated receptors, and the results 
showed that T143 →  A and T147 →  D replacements disrupted 
transportation to the cell surface and abolished the ability to 
respond to stimulation with ACTH, while the internalization of 
receptors carrying mutations T131 → A, T131 → D, and S280 → D 
was essentially undetectable. Thus, it was concluded that these 
four residues (T131, T143, T147, and S280) are crucial for ACTHR 
expression and functional regulation (86).
CONClUSiON
Data presented in this review are rather voluminous and reflect 
the heterogeneity of available information and applied research 
methodology. However, despite the difficulties, we hope that 
condensing this large body of work has proved useful and shall 
provide some novel insight. At the beginning of this article, we 
implied that functional ACTHR was discovered only in 2005 by 
Metherell et al. (39), while 1992 marks the discovery of the main 
subunit (38). This statement is clearly at odds with the currently 
used nomenclature, and the name ACTHR is even more at odds 
(the HGNC accepted name is MC2R). But, through this review, 
we have come to the conclusion that using term “receptor” is 
inappropriate because without MRAP1 ACTHR/MC2R does not 
bind to its ligand. Thus, while in this article we have ignored this, 
we propose that the name ACTHR should not be abandoned 
entirely but rather used to describe the molecular complex that 
specifically binds only ACTH (ACTHR-2 × MRAP1).
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